Latest Update on Cognitive Neurology: Biomarker-Guided Diagnosis and Disease-Modifying Therapy in Alzheimer Disease
The 2025 Alzheimer's Association guidelines establish a revolutionary paradigm shift: Alzheimer's disease is now defined as a biological disease diagnosed by biomarkers, not clinical symptoms alone, and blood-based biomarkers meeting specific performance thresholds can replace CSF or amyloid PET for confirming AD pathology before initiating disease-modifying therapies. 1, 2
Diagnostic Framework: The Biomarker-First Approach
Blood-Based Biomarkers as First-Line Diagnostic Tools
The most significant update is the validation of blood-based biomarkers (BBMs) for clinical use. BBMs with ≥90% sensitivity and ≥90% specificity can substitute for amyloid PET or CSF testing in patients with cognitive impairment presenting to specialized memory clinics. 2 This represents a fundamental shift from invasive testing to accessible blood tests.
Specific BBM analytes meeting these thresholds include:
- Plasma p-tau217 (phosphorylated tau-217)
- Ratio of p-tau217 to non-p-tau217 ×100 (%p-tau217)
- Plasma p-tau181
- Plasma p-tau231
- Ratio of Aβ42 to Aβ40
Critical caveat: Many commercially available BBM tests do NOT meet these performance thresholds, especially using single cutoffs. Clinicians must verify the specific test's diagnostic accuracy before clinical use. 2
Algorithmic Approach to Biomarker Testing
For patients with established cognitive impairment (MCI or dementia) in specialty care settings:
Initial evaluation: Structured history covering cognition, daily function, mood/behavior, and sensorimotor function, plus collateral informant input 1
Structural imaging first: Brain MRI or CT to exclude other pathologies and assess neurodegeneration patterns 1
Biomarker confirmation pathway:
- Option A (Preferred for accessibility): High-performance BBM test (≥90% sensitivity/specificity) to confirm amyloid pathology 2
- Option B: CSF analysis for Aβ42 and tau/p-tau if diagnostic uncertainty persists after structural imaging 1
- Option C: Amyloid PET if uncertainty remains after structural imaging and/or CSF testing 1
Key principle: CSF biomarker results directly impact medical decision-making for disease-modifying therapies and are sufficient for establishing amyloid-beta pathology, which MUST be confirmed before initiating treatment. 1 BBMs meeting performance thresholds now serve this same confirmatory role. 2
When to Use FDG PET or SPECT
FDG PET should be considered when diagnostic uncertainty persists after structural imaging, particularly to differentiate AD from frontotemporal dementia or other non-AD dementias. Avoid FDG PET in advanced dementia stages as it shows diffuse global hypometabolism regardless of cause. 1 SPECT can substitute when FDG PET is unavailable. 1
Disease-Modifying Therapy Eligibility
Mandatory Prerequisites
Before initiating any disease-modifying therapy:
- Confirmed presence of amyloid-beta pathology via BBM (≥90% sensitivity/specificity), CSF biomarkers, or amyloid PET 1, 2
- Established cognitive-behavioral syndrome (MCI or mild dementia stage)
- Comprehensive evaluation ruling out other contributing pathologies
Biological Staging System
The 2024 revised NIA-AA criteria introduce biological staging independent of clinical symptoms 3:
Core 1 biomarkers (early-changing):
- Amyloid PET, CSF, or high-accuracy plasma biomarkers (especially p-tau217)
- Abnormal Core 1 biomarker = sufficient to diagnose AD biologically
Core 2 biomarkers (later-changing):
- Tau PET and additional biofluid markers
- Provide prognostic information and increase confidence AD is causing symptoms
Clinical staging runs parallel:
- Stage 0: Asymptomatic with genetic risk, no biomarker abnormality
- Stage 1: Asymptomatic with biomarker evidence
- Stage 2: Transitional cognitive decline (including subjective complaints)
- Stage 3: MCI
- Stage 4: Mild dementia
- Stage 5: Moderate dementia
- Stage 6: Severe dementia
Critical Implementation Considerations
Pretest Probability Matters
Biomarker interpretation requires considering:
- Age (amyloid and tau pathology increase with age even without clinical AD)
- Clinical presentation and risk profile
- Possibility of multiple pathologies (common in older adults)
- Atypical presentations (early MCI, logopenic variant primary progressive aphasia)
BBMs are most useful when diagnostic confidence is intermediate, not when diagnosis is already clear or highly unlikely. 1, 2
Population-Level Limitations
Do NOT use BBMs for:
- Asymptomatic population screening (not recommended) 4
- Primary care settings without specialty consultation 5, 6
- Populations not represented in validation studies (performance may vary by race, ethnicity, comorbidities) 5, 6
Common Pitfalls to Avoid
Using low-performance BBM tests: Verify your specific test meets ≥90% sensitivity/specificity thresholds 2
Ignoring copathologies: Vascular disease, Lewy body pathology, TDP-43 proteinopathy commonly coexist. Biomarkers for these are emerging but not yet clinically validated (except alpha-synuclein seed amplification assays for Lewy body disease). 1
Misinterpreting indeterminate results: Not all results are clearly positive or negative; intermediate values require clinical judgment and may necessitate additional testing 2, 6
Bypassing comprehensive clinical evaluation: Biomarkers do NOT replace thorough cognitive assessment, functional evaluation, and neurologic examination 2
Emerging Paradigms
Multi-threshold testing and biomarker combinations are evolving approaches that may further refine diagnostic accuracy beyond single-cutoff strategies. 2 Plasma GFAP (glial fibrillary acidic protein) reflects astrocytic activation and adds prognostic value. 1 Neurofilament light chain indicates neurodegeneration but lacks AD specificity. 3
The field is rapidly evolving: Guidelines emphasize the need for living updates as evidence accumulates, particularly regarding BBM performance in diverse real-world populations and optimal biomarker combinations. 2, 6
Practical Workflow for Specialty Care
Step 1: Patient presents with cognitive complaints to memory clinic
Step 2: Obtain structured history (patient + informant), perform mental status examination and dementia-focused neurologic exam
Step 3: Order brain MRI to exclude structural lesions and assess atrophy patterns
Step 4: If AD suspected but diagnostic uncertainty remains, order high-performance BBM test (p-tau217 preferred) 2
Step 5: If BBM positive and clinical syndrome consistent with AD:
- Diagnose AD biologically
- Stage clinically (MCI vs. mild dementia)
- Discuss disease-modifying therapy eligibility
- Consider Core 2 biomarkers (tau PET) for prognostic information if needed
Step 6: If BBM negative, consider alternative diagnoses or proceed to CSF/amyloid PET if clinical suspicion remains high
Step 7: If BBM indeterminate or unavailable, proceed to CSF testing or amyloid PET per appropriate use criteria 1
This algorithmic approach prioritizes patient outcomes by enabling earlier, more accurate diagnosis and timely access to disease-modifying therapies while avoiding unnecessary invasive procedures through validated blood tests.